Human Infections with Borna Disease Virus 1 (BoDV-1) Primarily Lead to Severe Encephalitis: Further Evidence from the Seroepidemiological BoSOT Study in an Endemic Region in Southern Germany.

Borna disease virus 1 (BoDV-1) ELISA diagnostics encephalitis endogenous Borna-like elements epidemiology indirect immunofluorescence assay (iIFA) linear epitope mapping molecular mimicry solid organ transplantation

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
09 01 2023
Historique:
received: 27 11 2022
revised: 03 01 2023
accepted: 04 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

More than 40 human cases of severe encephalitis caused by Borna disease virus 1 (BoDV-1) have been reported to German health authorities. In an endemic region in southern Germany, we conducted the seroepidemiological BoSOT study ("BoDV-1 after solid-organ transplantation") to assess whether there are undetected oligo- or asymptomatic courses of infection. A total of 216 healthy blood donors and 280 outpatients after solid organ transplantation were screened by a recombinant BoDV-1 ELISA followed by an indirect immunofluorescence assay (iIFA) as confirmatory test. For comparison, 288 serum and 258 cerebrospinal fluid (CSF) samples with a request for tick-borne encephalitis (TBE) diagnostics were analyzed for BoDV-1 infections. ELISA screening reactivity rates ranged from 3.5% to 18.6% depending on the cohort and the used ELISA antigen, but only one sample of a patient from the cohort with requested TBE diagnostics was confirmed to be positive for anti-BoDV-1-IgG by iIFA. In addition, the corresponding CSF sample of this patient with a three-week history of severe neurological disease tested positive for BoDV-1 RNA. Due to the iIFA results, all other results were interpreted as false-reactive in the ELISA screening. By linear serological epitope mapping, cross-reactions with human and bacterial proteins were identified as possible underlying mechanism for the false-reactive ELISA screening results. In conclusion, no oligo- or asymptomatic infections were detected in the studied cohorts. Serological tests based on a single recombinant BoDV-1 antigen should be interpreted with caution, and an iIFA should always be performed in addition.

Identifiants

pubmed: 36680228
pii: v15010188
doi: 10.3390/v15010188
pmc: PMC9867173
pii:
doi:

Banques de données

DRKS
['DRKS00025180']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Emerg Infect Dis. 2021 May;27(5):1371-1379
pubmed: 33900167
Lancet Infect Dis. 2020 Apr;20(4):467-477
pubmed: 31924550
Philos Trans R Soc Lond B Biol Sci. 2013 Aug 12;368(1626):20120499
pubmed: 23938751
J Occup Med Toxicol. 2022 Jun 9;17(1):13
pubmed: 35681207
Cell Rep. 2015 Sep 8;12(10):1548-54
pubmed: 26321645
Lancet. 1999 Dec 4;354(9194):1973-4
pubmed: 10622306
Cell Rep Med. 2022 Jan 18;3(1):100499
pubmed: 35106511
J Gen Virol. 2016 Dec;97(12):3215-3224
pubmed: 27902378
Eur J Biochem. 1997 May 15;246(1):252-7
pubmed: 9210491
PLoS One. 2014 Apr 03;9(4):e93659
pubmed: 24699636
Nature. 2010 Jan 7;463(7277):84-7
pubmed: 20054395
J Virol. 1994 Dec;68(12):7669-75
pubmed: 7966555
N Engl J Med. 2018 Oct 4;379(14):1377-1379
pubmed: 30281984
Sci Rep. 2019 Dec 27;9(1):20154
pubmed: 31882942
J Gen Virol. 1986 Feb;67 ( Pt 2):235-41
pubmed: 3080548
J Biol Chem. 1998 Apr 10;273(15):9007-12
pubmed: 9535888
Biol Psychiatry. 2002 Jun 15;51(12):979-87
pubmed: 12062882
Acta Neuropathol. 2019 Jun;137(6):1017-1019
pubmed: 30953131
Acta Neuropathol. 2019 Oct;138(4):653-665
pubmed: 31346692
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4184-8
pubmed: 1693432
Emerg Microbes Infect. 2022 Dec;11(1):6-13
pubmed: 34783638
J Virol. 2001 Aug;75(15):7078-85
pubmed: 11435588
N Engl J Med. 2015 Jul 9;373(2):154-62
pubmed: 26154788
Emerg Microbes Infect. 2022 Dec;11(1):1843-1856
pubmed: 35788177
N Engl J Med. 2018 Oct 4;379(14):1375-1377
pubmed: 30281979
PLoS One. 2015 Aug 27;10(8):e0137018
pubmed: 26313904
Adv Virus Res. 2020;107:159-222
pubmed: 32711729
BMC Infect Dis. 2021 Aug 10;21(1):787
pubmed: 34376142
J Virol. 2021 Jun 24;95(14):e0203020
pubmed: 33952640

Auteurs

Markus Bauswein (M)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.

Lisa Eidenschink (L)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.

Gertrud Knoll (G)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.

Bernhard Neumann (B)

Department of Neurology, Donau-Isar-Klinikum Deggendorf, 94469 Deggendorf, Germany.
Department of Neurology, University of Regensburg, Bezirksklinikum, 93053 Regensburg, Germany.

Klemens Angstwurm (K)

Department of Neurology, University of Regensburg, Bezirksklinikum, 93053 Regensburg, Germany.

Saida Zoubaa (S)

Department of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany.

Markus J Riemenschneider (MJ)

Department of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany.

Benedikt M J Lampl (BMJ)

Regensburg Department of Public Health, 93059 Regensburg, Germany.
Department of Epidemiology and Preventive Medicine, University of Regensburg, 93053 Regensburg, Germany.

Matthias Pregler (M)

Regensburg Department of Public Health, 93059 Regensburg, Germany.

Hans Helmut Niller (HH)

Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.

Jonathan Jantsch (J)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, 50935 Cologne, Germany.

André Gessner (A)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.

Yvonne Eberhardt (Y)

Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.

Gunnar Huppertz (G)

Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.

Torsten Schramm (T)

Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.

Stefanie Kühn (S)

Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.

Michael Koller (M)

Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.

Thomas Drasch (T)

Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.

Yvonne Ehrl (Y)

Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.

Bernhard Banas (B)

Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.

Robert Offner (R)

Institute of Clinical Chemistry and Laboratory Medicine, Department of Transfusion Medicine, University Hospital Regensburg, 93053 Regensburg, Germany.

Barbara Schmidt (B)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.

Miriam C Banas (MC)

Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH